SG11202001707PA - Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease - Google Patents

Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Info

Publication number
SG11202001707PA
SG11202001707PA SG11202001707PA SG11202001707PA SG11202001707PA SG 11202001707P A SG11202001707P A SG 11202001707PA SG 11202001707P A SG11202001707P A SG 11202001707PA SG 11202001707P A SG11202001707P A SG 11202001707PA SG 11202001707P A SG11202001707P A SG 11202001707PA
Authority
SG
Singapore
Prior art keywords
patients
enhancing
methods
cardiac function
fabry disease
Prior art date
Application number
SG11202001707PA
Other languages
English (en)
Inventor
Jeff Castelli
Jay Barth
Nina Skuban
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202001707P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of SG11202001707PA publication Critical patent/SG11202001707PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202001707PA 2017-08-28 2018-08-28 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease SG11202001707PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
PCT/US2018/048257 WO2019046244A1 (en) 2017-08-28 2018-08-28 METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE

Publications (1)

Publication Number Publication Date
SG11202001707PA true SG11202001707PA (en) 2020-03-30

Family

ID=63528948

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001707PA SG11202001707PA (en) 2017-08-28 2018-08-28 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Country Status (26)

Country Link
US (1) US20200222377A1 (https=)
EP (3) EP4588476A1 (https=)
JP (3) JP7755929B2 (https=)
KR (2) KR102790184B1 (https=)
CN (1) CN111770753A (https=)
AR (1) AR112482A1 (https=)
AU (2) AU2018326364B2 (https=)
CA (1) CA3074450C (https=)
CL (1) CL2020000491A1 (https=)
DK (2) DK3675853T3 (https=)
EA (1) EA202090564A1 (https=)
ES (2) ES2931054T3 (https=)
FI (1) FI4176877T3 (https=)
HR (2) HRP20250064T1 (https=)
HU (2) HUE060287T2 (https=)
IL (3) IL272893B2 (https=)
LT (2) LT4176877T (https=)
MX (2) MX2020002229A (https=)
PL (2) PL4176877T3 (https=)
PT (2) PT4176877T (https=)
RS (2) RS66515B1 (https=)
SG (1) SG11202001707PA (https=)
SI (1) SI4176877T1 (https=)
SM (2) SMT202200459T1 (https=)
TW (1) TWI845479B (https=)
WO (1) WO2019046244A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
IL272893B2 (en) 2017-08-28 2024-07-01 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
CN111344912B (zh) 2017-08-28 2021-12-28 约翰·梅扎林瓜联合股份有限公司 同轴电缆连接器的天气防护壳体

Also Published As

Publication number Publication date
SMT202200459T1 (it) 2023-01-13
JP2025138638A (ja) 2025-09-25
MX2020002229A (es) 2020-07-20
TWI845479B (zh) 2024-06-21
RS63742B1 (sr) 2022-12-30
PT3675853T (pt) 2022-11-28
HRP20250064T1 (hr) 2025-03-14
KR20250049561A (ko) 2025-04-11
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
EP3675853A1 (en) 2020-07-08
KR102790184B1 (ko) 2025-04-01
RS66515B1 (sr) 2025-03-31
IL272893B2 (en) 2024-07-01
IL310648A (en) 2024-04-01
SI4176877T1 (sl) 2025-03-31
AR112482A1 (es) 2019-10-30
EP3675853B1 (en) 2022-09-07
US20200222377A1 (en) 2020-07-16
AU2018326364B2 (en) 2024-08-29
IL272893A (en) 2020-04-30
CL2020000491A1 (es) 2020-09-11
IL272893B1 (en) 2024-03-01
DK4176877T3 (da) 2025-02-24
EP4176877B1 (en) 2024-12-04
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
LT3675853T (lt) 2022-12-12
EP4588476A1 (en) 2025-07-23
HUE060287T2 (hu) 2023-02-28
LT4176877T (lt) 2025-02-10
HRP20221366T1 (hr) 2023-01-06
TW201919619A (zh) 2019-06-01
ES2931054T3 (es) 2022-12-23
PL3675853T3 (pl) 2022-12-27
JP2020531550A (ja) 2020-11-05
AU2018326364A1 (en) 2020-04-09
DK3675853T3 (da) 2022-11-28
BR112020003974A2 (pt) 2020-09-01
ES3013820T3 (en) 2025-04-15
PT4176877T (pt) 2025-02-24
PL4176877T3 (pl) 2025-04-07
AU2024266945A1 (en) 2024-12-19
FI4176877T3 (fi) 2025-03-06
CN111770753A (zh) 2020-10-13
WO2019046244A1 (en) 2019-03-07
JP2023051998A (ja) 2023-04-11
CA3074450C (en) 2024-10-01
JP7755929B2 (ja) 2025-10-17
CA3074450A1 (en) 2019-03-07
KR20200044908A (ko) 2020-04-29
HUE070433T2 (hu) 2025-06-28
EP4176877A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
IL272893A (en) Methods for increasing and/or stabilizing cardiac functions in patients with Fabry disease
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
EP3242709A4 (en) Cardiac stimulation of atrial-ventricle pathways and/or associated tissue
IL249580A0 (en) Methods for anesthetizing nerve tissue in the trigeminal nerve pathway and their medical uses
EP3319683A4 (en) Implantable nerve stimulator having internal electronics without asic and methods of use
HUE065152T2 (hu) Fluor-fenil-béta-hidroxietilaminok és alkalmazásuk hiperglikémia kezelésében
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
IL273470A (en) Semaglutide in medical treatment
IL269083A (en) Methods for preventing and treating heart disease
GB201709840D0 (en) Methods and medical uses
HUE064761T2 (hu) Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
ITUA20163417A1 (it) Fat and medical uses thereof
IL274773A (en) A pyrimidine sulfamide derivative and a method of its preparation and medical application
EP3644753A4 (en) METHODS FOR MAINTAINING AND IMPROVING RENAL FUNCTION IN PATIENTS WITH RENAL DISEASE AND STANDARD TREATMENT THERAPY
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
EP3346935A4 (en) Recovery and processing of human embryos formed in vivo
HK40029560A (en) Methods and medical uses relating to the treatment of hypoglycaemia
Thongcharoen Acharn Dr. Somchai-A Good Person of Thai and Global Academic Societies
GB201806133D0 (en) Methods and medical uses
GB201709837D0 (en) Methods and medical uses
EP3288562A4 (en) Method for improving kidney and/or heart function in patients with kidney disease